Petra Duprez - Biotage AB Chief Officer

BIOT Stock

SEK 151.70 0.70 0.46%

Insider

Petra Duprez is Chief Officer of Biotage AB

Age	58
Phone	46 18 56 59 00
Web	https://www.biotage.com

Biotage AB Management Efficiency

The company has return on total asset (ROA) of 0.109 % which means that it generated a profit of $0.109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1785 %, meaning that it generated $0.1785 on every $100 dollars invested by stockholders. Biotage AB's management efficiency ratios could be used to measure how well Biotage AB manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Biotage AB to Peers

Predict price of Biotage AB

Biotage AB has accumulated 180 M in total debt with debt to equity ratio (D/E) of 26.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biotage AB has a current ratio of 2.52, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Biotage AB until it has trouble settling it off, either with new capital or with free cash flow. So, Biotage AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biotage AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biotage to invest in growth at high rates of return. When we think about Biotage AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Klaus Sindahl	Hansa Biopharma AB	N/A
	Anne Lanner	Hansa Biopharma AB	54
	Ravinder Chahil	Zealand Pharma AS	N/A
	Stefan MBA	BioInvent International AB	60
	Ivan Moller	Zealand Pharma AS	51
	Danilo Verge	Zealand Pharma AS	N/A
	Jennifer McCann	Orphazyme AS	N/A
	Soren Therkildsen	GomSpace Group AB	41
	Katja Margell	Hansa Biopharma AB	N/A
	Hanne Bak	Zealand Pharma AS	70
	Thomas Pfister	GomSpace Group AB	47
	Bjrn Frendus	BioInvent International AB	50
	Henriette Wennicke	Zealand Pharma AS	N/A
	Troels Dalsgaard	GomSpace Group AB	37
	Lani Morvan	Zealand Pharma AS	N/A
	Eduardo Cruz	GomSpace Group AB	40
	Emanuel Bjrne	Hansa Biopharma AB	50
	Christina Bredal	Zealand Pharma AS	38
	Sylvie Ryckebusch	BioInvent International AB	N/A
	Mads Kronborg	Zealand Pharma AS	N/A
	MBA MSc	Orphazyme AS	53

Biotage AB , a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and academic institutions and commercial, hospitalbio-analytical, and forensic laboratories, as well as laboratories within food and environmental analysis. Biotage AB operates under Medical Instruments Supplies classification in Sweden and is traded on Stockholm Stock Exchange. It employs 438 people. Biotage AB (BIOT) is traded on Stockholm Exchange in Sweden and employs 510 people.

Management Performance

	Return On Equity	0.18
	Return On Asset	0.11

Biotage AB Leadership Team

Elected by the shareholders, the Biotage AB's board of directors comprises two types of representatives: Biotage AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotage. The board's role is to monitor Biotage AB's management team and ensure that shareholders' interests are well served. Biotage AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotage AB's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Tomas Blomquist, CEO Pres
	Raffaella Bombarda, EVP Marketing
	Maja Nilsson, Chief Officer
	CS BSc, Ex Operations
	JonSverre Schanche, Chief Officer
	Olof Nord, Exec Devel
	Lars LLB, Chief Officer
	Petra Duprez, Chief Officer
	Jonas Stahlberg, Chief Auditor
	Scott Carr, Pres Americas

Biotage Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biotage AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	0.18
	Return On Asset	0.11
	Profit Margin	0.16 %
	Operating Margin	0.22 %
	Current Valuation	12.84 B
	Shares Outstanding	65.98 M
	Shares Owned By Insiders	0.58 %
	Shares Owned By Institutions	64.57 %
	Price To Earning	38.27 X
	Price To Book	8.12 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Biotage Stock Analysis

When running Biotage AB's price analysis, check to measure Biotage AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotage AB is operating at the current time. Most of Biotage AB's value examination focuses on studying past and present price action to predict the probability of Biotage AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotage AB's price. Additionally, you may evaluate how the addition of Biotage AB to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC